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Cytoskeleton-associated protein 4 (CKAP4) is a reversibly palmitoylated and phosphorylated transmembrane protein that
functions as a high-aﬃnity receptor for antiproliferative factor (APF)—a sialoglycopeptide secreted from bladder epithelial cells
of patients with interstitial cystitis (IC). Palmitoylation of CKAP4 by the palmitoyl acyltransferase, DHHC2, is required for its cell
surface localization and subsequent APF signal transduction; however, the mechanism for APF signal transduction by CKAP4 is
unknown.Inthispaper,wedemonstratethatAPFtreatmentinducesserinephosphorylationofresiduesS3,S17,andS19ofCKAP4
and nuclear translocation of CKAP4. Additionally, we demonstrate that CKAP4 binds gDNA in a phosphorylation-dependent
manner in response to APF treatment, and that a phosphomimicking, constitutively nonpalmitoylated form of CKAP4 localizes
to the nucleus, binds DNA, and mimics the inhibitory eﬀects of APF on cellular proliferation. These results reveal a novel role for
CKAP4 as a downstream eﬀecter for APF signal transduction.
1.Introduction
Cytoskeleton-associated protein 4 (CKAP4; also known as
CLIMP-63, ERGIC-63, and p63) is a 63kDa, reversibly
palmitoylated and phosphorylated, type II transmembrane
(TM) protein, originally identiﬁed as a resident of the endo-
plasmic reticulum/Golgi intermediate complex (ERGIC) [1–
5]. The ﬁrst report describing CKAP4 [1] (referring to it as
“p62”) demonstrated that its palmitoylation peaked during
mitosis and suggested that palmitoylation may be an impor-
tant regulator of vesicular transport between various mem-
branous compartments. Soon thereafter, Schweizer and col-
leagues cloned CKAP4 and identiﬁed membrane-proximal
cysteine 100 (C100) as the site for palmitoylation [4]. More
recently, DHHC2 was identiﬁed as the palmitoyl acyltrans-
ferase (PAT) that palmitoylates CKAP4 at C100 [6].
CKAP4 is localized prominently to the endoplasmic
reticulum (ER). One major function of CKAP4 is to anchor
rough ER to microtubules, organizing the overall structure
of ER with respect to the microtubule network [3–5, 7, 8].
The binding of CKAP4 to microtubules is regulated by
phosphorylationofthreecriticalserineresidues(S3,S17,and
S19) located in its cytosolic, N-terminal domain (Figure 1)
[2]. CKAP4 is unique among microtubule binding proteins
in at least one respect: it is a TM protein. However, it
is similar to many other microtubule-binding proteins in
that phosphorylation blocks its ability to bind microtubules
[9]. Overexpression of a mutant version of CKAP4 that
mimics phosphorylation of three serine residues (S3E, S17E,
and S19E) within the microtubule binding domain results
in a restructuring or “collapse” of the ER around the
nucleus without any observable eﬀect on the microtubule
network. Similar eﬀects on the ER structure occurred when
a deletion mutant of CKAP4 lacking the same serine residues
was overexpressed in cells. Conversely, overexpression of a
full-length, phosphorylation-incompetent (S3A, S17A, and
S 1 9 A )m u t a n to fC K A P 4c o l o c a l i z e dw i t ha n dw a sa b l et o
bundle microtubules similar to wild-type CKAP4 [7].
CKAP4 is also expressed on the plasma membrane (PM).
Palmitoylation by DHHC2 is required for expression of2 International Journal of Cell Biology
S3 • Serine phosphorylation
S17/19 • Serine phosphorylation
N-terminus
C100 • Palmitoylation
Cytoplasmic
ER-luminal/
extracellular
2
21
Microtubule/ER
rearrangement
24
101
Required for linking
ER to microtubules
C-terminus
ER/plasma membrane
+
+
+
+
+
+
+
Leucine
zipper
Amphipathic
alpha helix
Nuclear localization signal
M9-like “RGGGGGGGK”
β-arrestin
binding site
−
−
−
−
−
−
−
Figure 1: CKAP4 domains. CKAP4 is a 63kDa, oligomeric, type II, single-pass TM domain protein that is palmitoylated and phos-
phorylated. The luminal/extracellular domain contains an amphipathic alpha helical region (506-KVQEQVHTLLSQDQAQAARLPPQD
FLDRLSSLDNLKASVSQVEADLKMLRTAVDSLVAYSVKIETNENNLESAKGLLDDLRNDLDRLFVKVEKIHEKV-602) that is important for
oligomerization and a leucine zipper (468-LASTVRSLGETQLVLYGDVEELKRSVGELPSTVESL-504). Together, these regions are homolo-
gous to the DNA-binding domain of bZIP transcription factors. The cytoplasmic, N-terminus contains a cysteine residue adjacent to the
TM domain at position 100 that is palmitoylated (a modiﬁcation that is important for traﬃcking from the ER to the PM), and three serine
residues(S3,S17,andS19)thatarerequiredforphosphorylation-dependentbindingofCKAP4tothemicrotubulecytoskeleton.Tworegions
in the cytoplasmic N-terminus are required for binding to and bundling microtubules, thereby maintaining the connection between the ER
and the cytoskeleton [3]. There is also a PQ protein-protein interaction domain (49-PHPQQHPQQHPQNQ-63) and a putative glycine-rich
nuclear localization signal sequence (65-GKGGHRGGGGGGGK-79).
CKAP4 on the cell surface [6], where it functions as a high-
aﬃnity receptor for antiproliferative factor (APF) [10]. APF
is a lipophilic, nine-residue sialoglycopeptide with an amino
acid sequence identical to the putative 6th TM domain of
Frizzled 8 [11]. APF is present in the urine of patients with
interstitial cystitis (IC), a chronic, painful bladder disease
with a poorly understood etiology [12]. Exposing cells to
APF in vitro dramatically alters gene expression and blocks
proliferation of normal bladder epithelial cells and cancer
cell lines including bladder (T24) and cervical (HeLa)
adenocarcinoma, mimicking critical aspectsof thepathology
of the bladder epithelium in IC patients [6, 11, 13, 14]. The
IC50 of synthetic and puriﬁed APF in proliferation assays is
∼1nM[14,15],indicatingthattheaﬃnityofAPFforCKAP4
is high.
Previously, we observed an increase in the nuclear
abundance of CKAP4 in HeLa cells following exposure to
APF [6]. Importantly, this APF-induced change in CKAP4
localization was dependent on palmitoylation by DHHC2.
ConcurrentwiththeincreasednuclearabundanceofCKAP4,
the expression level of several genes, (i.e., vimentin, zonula
occludens-1, and E-cadherin) changed signiﬁcantly in HeLa
and normal bladder epithelial cells following APF exposure
[6, 10, 13, 16]. These genes are among thirteen others
shown to have signiﬁcantly altered expression in bladder
tissue from IC patients and known to be involved in theInternational Journal of Cell Biology 3
Table 1: Mutant constructs used to study CKAP4 phosphorylation and palmitoylation. CKAP4 mutants that mimic constitutive depalmitoyla-
tion and various states of serine (S3, S17 and S19) phosphorylation were generated to determine their eﬀect on the subcellular distribution
of CKAP4 in response to APF. CKAP4SΔE translocated from the PM to the nucleus in response to APF; CKAP4SΔA localized to the PM
but did not translocate to the nucleus in response to APF; none of the C100S mutants were expressed on the PM; CKAP4C100S/SΔEw a s
expressedinthenucleus.TheresultsindicatethatCKAP4mustbepalmitoylatedforPMexpressionanddepalmitoylatedandphosphorylated
for translocation to the nucleus. A summary of these results are provided in the table.
Name Mutations Comments posttranslational
modiﬁcations Resting distribution Distribution after APF
wild-type (WT) CKAP4 none expressed or endogenous PM, ER > nucleus
CKAP4 C100S C100S constitutively depalmitoylated ER = ER
CKAP4 SΔA S3A, S17A, S19A constitutively
dephosphorylated PM, ER = PM, ER
CKAP4 C100S/SΔA C100S, S3A, S17A, S19A
constitutively
depalmitoylated,
constitutively
dephosphorylated
ER ER
CKAP4 SΔE S3E, S17E, S19E mimics phosphorylation PM, ER > nucleus
CKAP4 C100S/SΔE C100S, S3E, S17E, S19E
constitutively
depalmitoylated, mimics
phosphorylation
Nucleus = nucleus
regulation of proliferation, cell adhesion, and tumorigenesis
[17–19]. The redistribution of CKAP4 to the nucleus and
the concurrent changes in gene expression suggest that
APF induces speciﬁc changes in the palmitoylation and/or
phosphorylation state of CKAP4, and that these changes
aﬀect its subcellular distribution and function within the
cell.Consequently,wegeneratedCKAP4mutantsthatmimic
constitutive depalmitoylation and various states of serine
phosphorylation to determine their eﬀect on the subcellular
distribution of CKAP4 in response to APF.
Our results show that APF increases serine phosphoryla-
tionofCKAP4,andthatphosphorylationofresiduesS3,S17,
and S19 are required for its nuclear translocation; moreover,
a phosphomimicking, constitutively nonpalmitoylated form
of CKAP4 localizes to the nucleus, binds DNA, and mimics
the inhibitory eﬀects of APF on cellular proliferation. These
results reveal a novel role for CKAP4 in APF-dependent
signaling from the plasma membrane to the nucleus and
suggest that CKAP4 may regulate transcription by binding
directly to DNA.
2.ExperimentalProcedures
2.1. DNA Constructs. A vector construct containing wild-
type CKAP4 (WT CKAP4) fused in-frame to the N-terminus
of the V5 and 6xHis epitope tags in the mammalian expres-
sion vector pcDNA3.1V5His6-TOPO (Invitrogen, Carlsbad,
CA) was generated by PCR using CKAP4-speciﬁc primers
and cDNA from HeLa cells. A palmitoylation-incompetent
form of CKAP4 (CKAP4C100S) was created by site-directed
mutagenesisofthewild-typevectorconstruct(Stratagene,La
Jolla, CA) to change the cysteine at position 100 to serine.
A series of CKAP4 mutants that mimic depalmitoylation
and/or constitutive dephosphorylation and phosphorylation
were constructed by site-directed mutagenesis of the WT
CKAP4 or CKAP4C100S vector constructs as described in
Table 1. cDNA encoding the extracellular domain of CKAP4
(C-terminal residues 126–501) was generated by PCR and
cloned in-frame with the His6 epitope tag of pRSET-B
(Invitrogen) at the 5  end. The accuracy of all constructs was
veriﬁed by DNA sequencing.
2.2. Cell Culture and Transfections. HeLa (ATCC #CCL-2;
AmericanTypeCultureCollection, Manassas, VA) cellswere
maintainedinDulbecco’smodiﬁedEagle’smedium(DMEM)
containing 10% fetal bovine serum (FBS), 100U/mL peni-
cillin, and 100μg/mL streptomycin and 1μg/mL fungi-
zone (all from Invitrogen). Cells were trans-fected using
FuGENE6 reagent (Roche, Basel, Switzerland) according to
the manufacturer’s instructions.
2.3. Immunocytochemistry. HeLa cells expressing WT
CKAP4 or CKAP4 mutants that mimic depalmitoylation
and/or constitutive dephosphorylation and phosphorylation
(see Table 1) were seeded at a density of 2 × 104 cells/well in
8-well LabTek chamber slides (Nalge Nunc, Rochester, NY)
and grown to semiconﬂuence in DMEM medium containing
10% FBS, 100U/mL penicillin, 100μg/mL streptomycin,
1μg/mL fungizone, and 0.4mg/mL G418 (all from Invitro-
gen). Cells were ﬁxed for 20 minutes with 3% paraformalde-
hyde in phosphate-buﬀered saline (PBS), permeabilized with
0.1% Triton X-100 in PBS, and blocked in PBS/5% normal
goat serum (NGS). The following primary antibodies were
used: mouse mAb G1/296 against CKAP4 (“anti-CLIMP-63”,
diluted 1:100, Alexis Biochemicals, San Diego, CA), rabbit
pAb against tubulin (diluted 1:100, Abcam, Cambridge,
MA), rabbit pAb against ﬁbrillarin (diluted 1:100, Abcam),
and ﬂuorescein isothiocyanate- (FITC-) conjugated mouse
mAb against the V5 epitope (diluted 1:500, Invitrogen).
Secondary antibodies were FITC-labeled goat anti-rabbit or
goat anti-mouse (diluted 1:1000, Invitrogen) and tetram-
ethyl rhodamine isothiocyanate- (TRITC-) labeled goat4 International Journal of Cell Biology
anti-mouse (diluted 1:1000, Jackson ImmunoResearch Lab-
oratories,WestGrove,PA).SlidesweremountedinSlowFade
Antifade reagent (Invitrogen) and imaged using a Nikon
TE2000 epiﬂuorescence microscope or Leica SP5II confocal.
2.4. Nuclear and Nucleolar Protein Isolation. HeLa cells
were serum-starved overnight and then treated with
20nM synthetic APF (Peptides International) for 24 hours.
Nuclear extracts were generated using the NE-PER kit
(ThermoFisher Scientiﬁc, Waltham, MA) according to
the manufacturer’s instructions. Nucleoli were isolated
using a variation on the method used by Busch and
coworkers in 1963 [20] as described by the Lamond lab
(http://www.lamondlab.com/f7protocols.htm).Brieﬂy,APF-
treated or untreated HeLa cells were washed with cold PBS
(pH 7.4), trypsinized, and collected by centrifugation at
500 ×g for 5min. The cell pellets were resuspended in
15 volumes of a hypotonic buﬀer (10mM Tris-HCl, pH
7.4, 10mM NaCl, and 1mM MgCl2), incubated on ice for
30min, and then lysed by adding Nonidet P-40 to a ﬁnal
concentration of 0.3%. The samples were homogenized 10
times using a glass dounce homogenizer (0.4-mm clearance;
Kimberly/Kontes,Owens,IL)whilekeepingthehomogenizer
on ice. Nuclei were collected by centrifugation at 218 ×g
for 5min and resuspended in 10 volumes of 0.25M sucrose
containing 10mM MgCl2. Nuclei were then puriﬁed by
centrifugationat1430 ×gfor5minthrougha0.88Msucrose
cushion containing 0.05mM MgCl2.P u r i ﬁ e dn u c l e iw e r e
resuspended in 10 volumes of 0.34M sucrose containing
0.05mM MgCl2 and sonicated on ice for six, 10-second
bursts with 10-second intervals between each burst. Nucleoli
were then puriﬁed from the resulting homogenate by cen-
trifugation at 3000 ×g for 10min through a 0.88M sucrose
cushion containing 0.05mM MgCl2. Puriﬁed nucleoli were
resuspended in 0.34M sucrose containing 0.05mM MgCl2
for further analyses.
2.5. Immunoprecipitation. Lysates (500μg) from serum-
starved HeLa cells treated with 20nM APF or serum-starved
controls were immunoprecipitated with an mAb antibody
against CKAP4 (G1/296; 1μg mAb/100μg total protein
lysate; Alexis Biochemicals) overnight at 4◦C. Samples were
then bound to Protein A, washed (4X with RIPA/Empigen
buﬀer), eluted (4X LDS sample buﬀer; Invitrogen), boiled at
95◦C for 5min and resolved on a 4–12% Bis-Tris gel and
transferred to a nitrocellulose membrane under reducing
conditions. Western Blot analysis detected phosphoserine
on CKAP4 using primary mouse mAb, α-phosphoserine
antibody (Invitrogen; diluted 1:1000) and secondary, HRP-
conjugated goat anti-mouse (diluted 1:20,000, Jackson
ImmunoResearch Laboratories). The signal was detected on
ﬁlm by ECL (ThermoFisher Scientiﬁc). The membrane was
stripped and reprobed with a mouse mAb G1/296 against
CKAP4 (Alexis Biochemicals) to normalize the phosphoser-
ine signal to the amount of immunoprecipitated CKAP4.
Densitometric analysis of the immunoreactive bands was
performed using ImageJ, and the ratios of phosphorylated
to nonphosphorylated CKAP4 were determined.
2.6. Western Blot Analysis. Cells were lysed in ice-cold
RIPA buﬀer containing protease inhibitors (ThermoFisher
Scientiﬁc), sonicated, and centrifuged for 15 minutes at
4◦C. The supernatant protein concentration was measured
using the Micro BCA protein assay kit (ThermoFisher
Scientiﬁc). Proteins were separated by electrophoresis using
4–12% NuPAGE Novex Bis-Tris polyacrylamide gels in
MOPS running buﬀer (Invitrogen) and then transferred
to nitrocellulose. Membranes were blocked for 2 hours at
room temperature in TBST buﬀer (Tris-buﬀered saline, pH
7.4, with 0.1% Tween 20) containing 5% nonfat milk and
incubated with an mAb antibody against CKAP4 (G1/296;
diluted 1:1000; Alexis Biochemicals) overnight at 4◦C. The
membrane was subsequently washed with TBST, incubated
for 1 hour at room temperature in HRP-conjugated goat,
anti-mouse (diluted 1:20000; ThermoFisher Scientiﬁc) sec-
ondary antibody and developed by enhanced chemilumi-
nescence (ThermoFisher Scientiﬁc). To assess equal loading
of protein, the membranes were stripped and reprobed for
β-tubulin (diluted 1:1000; Abcam) and also for ﬁbrillarin
(diluted 1:1000; Abcam) to ensure the purity of the nuclear
fraction. The membranes were exposed to ﬁlm (BioMax AR,
Kodak, Rochester, NY) and the resulting images scanned at
300dpi. The protein bands of interest were quantiﬁed using
ImageJ and the integrated signal densities normalized to β-
tubulin (cytosol) or ﬁbrillarin (nuclear) and subsequently
expressed in terms of the fractional abundance relative to
untreated control cells.
2.7. 32PM e t a b o l i cL a b e l i n g .HeLa cells grown to ∼80%
conﬂuence in 10cm dishes were serum starved for three
hours and then metabolically labeled with 150μCi γ32P-ATP
for one hour. The cells were then exposed to APF (20nM; 24
hours) or left in serum-free medium (control) for 24 hours.
The cells were then harvested, washed three times in ice-cold
PBS, and the nuclear fraction was isolated using the NE-
PER kit (ThermoFisher Scientiﬁc). Equal quantities of each
fraction were separated by SDS-PAGE and transferred to
nitrocellulose for Western Blot analysis using a CKAP4 mAb
(G1/296; diluted 1:500; Alexis Biochemicals) as described
above.FollowingtheWesternBlot,themembranewasrinsed
in 1% H2O2 for one minute to eliminate the chemilumines-
cent signal and then wrapped in plastic wrap and exposed to
ﬁlm for 12 hours to detect the phosphorylated proteins.
2.8. Cell Surface Biotinylation. Sulfo-NHS-biotin (Ther-
moFisher Scientiﬁc) was dissolved in serum-free DMEM
to a ﬁnal concentration of 0.5mg/mL. HeLa cells were
grown in serum-free medium for 36 hours (10cm dishes
at ∼80% conﬂuence), washed three times in PBS, and
the medium replaced with serum-free DMEM/Biotin. The
labeling reaction proceeded at 4◦C for 60 minutes. Next,
the cells were washed three times in PBS/100mM gylcine
to quench unreacted biotin. Serum-free DMEM containing
APF (20nM) or without APF (control) was added back
to the cells, which were then incubated at 37◦Cf o rf o u r
hours. Cells were harvested by trypsinization, washed three
times in PBS, and the nuclear protein fraction was isolatedInternational Journal of Cell Biology 5
using the NE-PER kit (ThermoFisher Scientiﬁc) according
to the manufacturer’s protocol. Equal quantities of protein
from each nuclear fraction were separated by SDS-PAGE and
then blotted to nitrocellulose. The membrane was blocked
overnight at 4◦Ci nT B S Tb u ﬀer containing 10% milk and
subsequently washed three times in TBS, once in TBST and
oncewithPBS.Themembranewasthenincubatedtwohours
atroomtemperatureinPBS/1%BSAcontainingStreptavidin
HRP (ThermoFisher Scientiﬁc) at a concentration of 1:500
dilution(0.02μg/mL).Themembranewasthenwashedthree
times (10 minutes each) at 4◦Ci nT B Sa n do n c ei nT B S T .
Biotinylated proteins on the membrane were detected using
ECL (ThermoFisher Scientiﬁc; Super Signal West Pico).
T h es a m em e m b r a n ew a ss u b s e q u e n t l yW e s t e r nB l o t t e d
simultaneously with antibodies to CKAP4 (G1/296; diluted
1:1000; Alexis Biochemicals) and ﬁbrillarin (diluted 1:100,
Abcam). The signal from the biotinylated CKAP4 in the
nuclear fraction was normalized to the nuclear abundance of
CKAP4 as determined by Western Blot and the total amount
of nuclear protein loaded into each lane as was determined
by the signal from ﬁbrillarin.
2.9. Genomic DNA Aﬃnity Chromatography (GDAC).
HeLa cells treated with APF (or control) or expressing
CKAP4C100S/SΔE (for 24–48 hours) were scraped into
gDNA binding buﬀer (20mM Tris [pH 7.5], 100mM KCl,
10% Glycerol, 1mM EDTA, 1mM DTT, 1mg/mL BSA, 0.1%
SDS) with 1X phosphatase inhibitor and 1X phosphatase
inhibitor cocktail 1 (both from ThermoFisher Scientiﬁc).
Proteins were extracted for 2 hours on ice and then the
insoluble fraction was pelleted by centrifugation at 15,000
×gf o r1 0m i n u t e sa t4 ◦C. Next, 15–100mg of gDNA
cellulose or cellulose alone (control; both from Sigma) was
added to the cleared supernatant and mixed by constant
inversion on a rotating wheel at 4◦Cf o rt w oh o u r st o
overnight. To capture the bacterially expressed C-terminus
of CKAP4, 0.4–40μg of puriﬁed protein (as determined by
the Micro BCA assay, ThermoFisher Scientiﬁc) was added
to 15–50mg gDNA-cellulose in 500μL of gDNA-binding
buﬀer and mixed as above at 4◦C. After proteins were
allowed to bind, the gDNA-cellulose or cellulose alone was
pelleted by centrifugation and washed with PBS three times.
This wash protocol was suﬃcient to remove nonspeciﬁcally
bound proteins and nonphosphorylated CKAP4 from the
cellulose alone and from the gDNA-cellulose. After the
ﬁnal wash, SDS-PAGE sample buﬀer was added to 10μL
of the supernatant previously removed from the gDNA
pellet, the cellulose, or gDNA-cellulose pellet. The samples
were heated for 5 minutes at 95◦C, separated by SDS-
PAGE, transferred to nitrocellulose, and probed with α-V5
antibody (mAb; 1: 5000; Invitrogen) followed by goat-α-
mouse-HRP (1:10,000, ThermoFisher Scientiﬁc) to detect
the transiently expressed CKAPC100S/SΔEo rα-CKAP4
(mAb G1/296; 1:1000; Alexis Biochemicals) followed by
goat-α-mouse-HRP (1:10,000, ThermoFisher Scientiﬁc) to
detect endogenous and/or transiently expressed CKAP4.
The signal was detected on ﬁlm using chemiluminescence
(SuperSignal West Pico, ThermoFisher Scientiﬁc).
3. Results
3.1. CKAP4 Translocates from the Plasma Membrane to
the Nucleus in Response to APF. Previously, we observed
by immunolocalization that CKAP4 is expressed on the
surface of HeLa cells and became more abundant in the
nucleus following APF exposure [6]. To conﬁrm that CKAP4
translocates to the nucleus in response to APF, we used three
diﬀerenttechniques—surfacelabeling,cellularfractionation,
and immunocytochemistry. First, we surface-labeled HeLa
cell proteins with sulfo-NHS biotin, a water soluble form
of biotin that does not pass through the PM and binds
only to primary amines of the extracellular portions of
proteins. We then treated the cells with APF for three hours,
isolated the nuclear protein fraction, and separated the
proteins by SDS PAGE followed by transfer to nitrocellulose
and detection with streptavidin-HRP. As demonstrated in
Figure 2(a), biotinylated CKAP4 protein was detected in
the nuclear fraction of APF-treated cells but not in the
nuclear protein fraction isolated from untreated cells. This
demonstrates that CKAP4 is present on the cell surface and
that it is internalized and translocates to the nucleus in
response to APF treatment.
To determine whether there is a fractional change in
nuclear abundance of CKAP4 in response to APF stim-
ulation, we performed Western Blot analysis on nuclear
and cytosolic protein fractions extracted from APF-treated
and untreated cells. We found that exposure of HeLa
cells to APF resulted in a ∼4-fold increase in the relative
abundance of CKAP4 in the nucleus (Figures 2(b) and
2(c)) conﬁrming our earlier observations [6]. Lastly, we
show by immunocytochemistry that transiently expressed,
wild-type (WT) CKAP4 localizes to the nucleus after APF
treatment (Figure 3(a)). Collectively, these data demonstrate
that CKAP4 translocates to the nucleus of HeLa cells after
APF treatment.
3.2. APF-Induced Nuclear Translocation of CKAP4 Is Regu-
lated by Serine Phosphorylation. Previously we showed that
DHHC2-mediatedpalmitoylationofCKAP4oncysteine-100
(C100) is required for its nuclear localization in response
to APF treatment [6]. Work by others has shown that
phosphorylation of serines 3, 17, and 19 (S3, S17, and
S19) also aﬀects CKAP4 subcellular distribution, promoting
disengagement from microtubules [7]. These ﬁndings sug-
gest that APF binding may alter the palmitoylation and/or
phosphorylation state of CKAP4, aﬀecting its subcellular
distribution and function within the cell. Consequently, we
generated CKAP4 mutants that mimic constitutive depalmi-
toylation and various states of serine phosphorylation to
examine the eﬀect of APF on their subcellular distribution
in HeLa cells using immunocytochemistry (Table 1). The
CKAP4 mutations included C100 to serine (C100S) to block
palmitoylation; mutation of S3, S17, and S19 to alanine
(SΔA) to block phosphorylation; mutation of the same
three serines to glutamic acid (SΔE) to mimic phosphory-
lation [7]. Each mutant was fused to a V5 epitope tag to
immunologically distinguish it from endogenous CKAP4.
Also, since phosphorylation regulates the association of6 International Journal of Cell Biology
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Figure 2: Surface-labeled CKAP4 translocates from the plasma membrane into the nucleus following APF exposure. (a) HeLa cell-surface
proteins were labeled with Sulfo NHS-biotin as described in Section 2. Following exposure to 20nM APF for 24 hours (or no treatment), the
cellswereharvestedandthenuclearproteinfractionwasisolated(PierceNE-PER),separatedbySDS-PAGE,andtransferredtonitrocellulose.
The membrane was then probed with streptavidin-HRP (1:5000; Pierce) to bind biotinylated proteins, and the signal was detected by ECL
(Pierce). Following detection of the biotinylated proteins from the nucleus, the (streptavidin) HRP on the membrane was inactivated by
incubating the blot in PBS containing 3% H2O2 and 1% sodium azide. The same membrane was then reprobed with antibodies to CKAP4
(“anti-CLIMP-63”, diluted 1:1000, Alexis Biochemicals) and ﬁbrillarin (a nuclear marker and loading control; Abcam; diluted 1:1000). (b)
HeLa cells were treated with APF (20nM) for 24 hours, which resulted in a signiﬁcant increase in the abundance of CKAP4 in the nucleus
compared to control samples. Treated cells were harvested and the nuclear and cytosolic fractions were isolated and separated by SDS-PAGE
asdescribedinSection 2.ProteinexpressionwasanalyzedbyWesternBlottingwithantibodiesforβ-tubulin(diluted1:1000,Abcam;loading
control for the nonnuclear fraction), CKAP4 (“anti-CLIMP-63”, diluted 1:1000, Alexis Biochemicals), and ﬁbrillarin (diluted 1:1000,
Abcam; loading control and speciﬁc marker for the nuclear fraction), and then with an HRP-conjugated anti-mouse secondary antibody
(1:20000; ThermoFisher Scientiﬁc). The proteins were detected by ECL (Pierce) with multiple exposures to ﬁlm. The integrated density of
the bands on the ﬁlm was measured using ImageJ. Exposure times were controlled to ensure that the signals on ﬁlm were not saturated. (c)
The nuclear/cytosolic ratio represents the relative distribution of CKAP4 in the nuclear versus cytosolic fractions extracted from cells treated
withorwithoutAPF.CKAP4abundanceintheAPF-treatedandcontrolsampleswerenormalizedforloadingtoβ-tubulinforthenonnuclear
fractions and to ﬁbrillarin for the nuclear fractions. The nuclear/cytosolic ratio for CKAP4 in the APF and control samples was determined
from these normalized values. The standard deviation describes the variability among the normalized, nuclear, and cytosolic ratios from
three independent experiments. A two tailed, paired t-test of the two data arrays (plus APF and control) indicate that the diﬀerence between
these ratios is signiﬁcant (P = 0.01; n = 3). Cells treated with APF stop dividing, so the 10cm dishes containing control and APF treated
cells contained fewer cells (and protein) at the end of the experiment, normalizing the CKAP4 signals to loading controls corrected for this
disparity. Fibrillarin is a well-characterized nuclear marker that is also known to localize to nucleoli. The data shown are representative of
four independent experiments.
CKAP4 with microtubules, we coimmunolabeled tubulin
andCKAP4tovisualizediﬀerencesintherelativelocalization
of CKAP4 within the microtubule network. Table 1 provides
a summary of the data.
As shown in Figure 3, we conﬁrmed that palmitoylation
was required for CKAP4 expression on the PM regardless of
the state of phosphorylation (see Figures 3(b), 3(d), 3(f)).
Importantly, when CKAP4 is not expressed on the PM, itInternational Journal of Cell Biology 7
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Figure 3: CKAP4 phosphorylation and palmitoylation regulate CKAP4 traﬃcking. CKAP4 mutants that mimic constitutive depalmitoylation
and various states of serine [3, 17, 19] phosphorylation were generated to determine the eﬀect of these two posttranslational modiﬁcations
on the subcellular distribution of CKAP4 in response to APF (see Table 1). HeLa cells were transfected for 24–36 hours with the construct
indicated to the left of each panel. Cells were serum starved for 6 hours and then treated with APF (20nM) for 18–24 hours. Subsequently,
the cells were ﬁxed in 4% buﬀered paraformaldehyde, permeabilized with 0.1% Triton X-100, and immunostained for (1) β-tubulin (red;
TRITC) and (2) V5 (green: FITC) (as described in Section 2) to distinguish the transfected, V5-epitope tagged WT (a) and mutant versions
of CKAP4 from endogenous CKAP4 (b)–(d). Mutant versions of CKAP4 that cannot be palmitoylated (C100S) or phosphorylated (SΔA)
do not translocate to the nucleus in response to APF. (e) Those that mimic phosphorylation (SΔE) translocate to the nucleus in response to
APF. (f) CKAP4C100SSΔE, which is constitutively depalmitoylated and phosphomimicking, is expressed primarily in the nucleus. Images
taken in each channel were superimposed to illustrate the distribution of mutant CKAP4 with respect to the cytoskeleton. The cells were
imaged by epiﬂuorescence or confocal microscopy at 60X and 63X, respectively, (Scale bars = 25 microns).
does not respond to APF by a change in subcellular dis-
tribution (Figures 3(b), 3(d), and 3(f)). CKAP4C100S/SΔA
expression was restricted to internal membranes and did
not change in response to APF (Figure 3(d)). CKAP4SΔA
was expressed throughout the cell, including the PM, and
resembled that of WT CKAP4 (Figures 3(a) and 3(c)). Treat-
ment of cells expressing CKAP4SΔA with APF did not cause
translocation of the mutant form of CKAP4 into the nucleus,
suggesting that CKAP4 must be phosphorylated on serine
residues 3, 17, and 19, thus disengaged from the microtubule
network,totranslocateintothenucleus.CKAP4SΔEwasalso
distributed throughout the cells including the PM, but in
contrast to CKAP4SΔA, APF treatment caused translocation
of CKAP4SΔE into the nucleus (Figure 3(e)). Surprisingly,
CKAP4C100S/SΔE was expressed primarily if not exclusively
in the nucleus (even in the absence of APF), and its
localization did not change in response to APF treatment
(Figure 3(f)). These data suggest that phosphorylation of
CKAP4 on serine residues 3, 17, and 19 are required for its
nuclear translocation in response to APF.
To test the idea that APF treatment promotes serine
phosphorylation of CKAP4, we used an antiphosphoserine
antibody to measure any change in phosphorylation of
endogenous CKAP4 from whole cell lysates in response to
APF. Serine phosphorylation of CKAP4 immunoprecipitated
from APF-treated HeLa cells was increased ∼5.0-fold com-
pared with CKAP4 immunoprecipitated from whole cell
lysates of untreated cells (Figure 4), demonstrating that APF
increases CKAP4 phosphorylation on serine residues.
3.3. Nuclear CKAP4 Is Phosphorylated following APF-Induced
Translocation. The observed increase in serine phosphoryla-
tion of endogenous CKAP4 and nuclear localization of the8 International Journal of Cell Biology
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Figure 4: APF induces serine phosphorylation of CKAP4. (a) APF treatment induces a signiﬁcant increase in serine phosphorylation
of CKAP4 as demonstrated by immunoprecipitation of CKAP4 followed immunoblotting to detect phosphoserine. Whole cell lysates
(500μg) from HeLa cells treated with 20nM APF or serum-starved controls were immunoprecipitated with CKAP4 antibody (Alexis)
overnight at 4◦C. Samples were then bound to Protein A, washed (4X with RIPA/Empigen buﬀer), eluted (4X LDS sample buﬀer;
Invitrogen), boiled at 95◦C for 5min and resolved on a 4–12% Bis-Tris gel and transferred to a nitrocellulose membrane under reducing
conditions. Western Blot analysis for pSer detected phospho-serine using primary (Invitrogen and secondary antibodies (goat anti-rabbit
HRP-labeled antibody; Pierce)) developed with Enhanced Chemiluminescence reagent (Pierce) and exposed to ﬁlm. The membrane was
stripped with Restore Stripping Buﬀer (Pierce) and reprobed for CKAP4 (Alexis) to normalize the phosphoserine signal to the amount
of immunoprecipitated CKAP4. (b) Densitometric analysis of the immunoreactive bands was done using ImageJ, and the ratios of
phosphorylated to nonphosphorylated CKAP4 were determined.
phosphomimicking CKAP4 mutants in response to APF sug-
gested that endogenous CKAP4 should be phosphorylated if
it is in the nucleus. To determine if nuclear CKAP4 is indeed
phosphorylated, we metabolically labeled cells with γ32P-
ATP, exposed them to APF, and isolated the nuclear fraction.
The level of phosphorylation was assessed by Western Blot
after separation of proteins by SDS-PAGE. In agreement
with previous experiments, the abundance of CKAP4 in the
nucleus increased following exposure to APF (Figure 5(a),
top panel). Nuclear CKAP4 was phosphorylated to an equal
degreeinbothAPF-stimulatedandcontrolcells(Figure 5(a),
bottom panel). The ratio of the CKAP4 phosphorylation
signal over the corresponding CKAP4 Western Blot signal
was the same for both (1.00 versus 0.975; APF treated versus
control) indicating that nuclear CKAP4 is phosphorylated.
In HeLa cells exposed to APF or cells transfected with
CKAP4C100S/SΔE, we observed by immunolabeling that
CKAP4 was not evenly distributed within the nucleus, but
rather appeared to be concentrated on nucleoli and other
unidentiﬁed subnuclear structures (data not shown). To
determine whether CKAP4 was associated with nucleoli, we
treated HeLa cells with APF for 24 hours and measured
the abundance of CKAP4 in the nucleolar and nuclear
fractions (nonnucleolar fraction of the nucleus) by Western
Blot(Figure 5(b)).OurresultsdemonstratethatAPFinduces
an association of CKAP4 with nucleoli (Figures 5(b) and
5(c)). Immunolocalization of CKAP4C100S/SΔEs u g g e s t e d
that it too associated with nucleoli (independent of APF
treatment). To conﬁrm this biochemically, we expressed
CKAP4C100S/SΔE in HeLa cells, isolated the nucleolar frac-
tion, and measured its association with nucleoli by Western
Blot. Figure 5 shows that CKAP4C100S/SΔE associates with
nucleoli to a greater degree than endogenous CKAP4 in
APF-treated cells. These data support the idea that CKAP4
becomes phosphorylated after binding to APF, and that
phosphorylation enhances its nuclear translocation.
3.4. CKAP4C100S/SΔE Behaves as an APF Mimetic. The
similarity between the nuclear localization of endogenous
CKAP4 following APF treatment and transiently expressed
CKAP4 C100S/SΔE suggested that the mutant may mimic
APF activity, such as inhibiting cellular proliferation. To
determine if this hypothesis was correct, we transfected
HeLa cells with varying quantities of CKAP4C100S/SΔE
cDNA and measured their proliferation over the course of
48 hours. Figure 6 shows that that transient expression of
CKAP4C100S/SΔE signiﬁcantly inhibits HeLa cell prolifera-
tion in a dose-dependent manner (versus mock transfected
cells), a result that is characteristic of cells exposed to APF [6,
11, 21]. These results indicate that CKAP4C100S/SΔEm a yInternational Journal of Cell Biology 9
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Figure 5:NuclearCKAP4isphosphorylatedfollowingAPF-inducedtranslocation.(a)CKAP4inthenuclearfractionwasphosphorylatedtothe
same degree in APF-treated and control cells as demonstrated by metabolic labeling with γ32P-ATP. The ratio of the CKAP4 phosphorylation
signal over the corresponding CKAP4 Western Blot signal was approximately the same for both (1.00 versus 0.975; APF treated versus
control). HeLa cells at ∼80% conﬂuence in 10cm dishes were serum starved for 3 hours then 150μCi γ32P - A T Pw a sa d d e dt oe a c hd i s hf o r
1 additional hour. Then the cells were either exposed to APF (20nM; 24 hours) or left in serum-free medium (control) for 24 hours.
At the end of 24 hours, the cells were harvested, washed three times in ice-cold PBS, and the nuclear and cytoplasmic fractions were
isolated using the NE-PER (Pierce). Equal quantities of each fraction were separated by SDS-PAGE and transferred to nitrocellulose. The
membrane was incubated overnight at 4◦Ci nα-CKAP4 antibody (1:500) in TBST and 1% milk, washed and incubated for six hours at
4◦C in a-mouse, HRP-conjugated secondary antibody (Pierce; 1:20,000) in TBST and 1% milk. CKAP4 bands were detected by enhanced
chemiluminescence (ECL; Pierce; 20 second exposure; left panel). Following the Western Blot, the membrane was rinsed in 1% H2O2
for 1 minute to eliminate the chemiluminescent signal then wrapped in plastic wrap and exposed to ﬁlm for 12 hours to detect the
phosphorylated proteins. Densitometric analysis of the immunoreactive bands was done using ImageJ, and the ratios of phosphorylated
to nonphosphorylated CKAP4 were determined. APF increases the association of CKAP4 with nucleoli. (b) and (c) Western Blot analysis
shows that treatment of HeLa cells with APF (20nM) increased the association of endogenous CKAP4 with the nucleolar fraction, and that
the constitutively depalmitoylated and phosphomimicking CKAP4 mutant, CKAP4C100S/SΔE, associated with the nucleolar fraction to a
greater extent than endogenous CKAP4 isolated from APF-treated cells. Nucleoli were isolated using a variation on the method published
by Busch and coworkers [20] as described by the Angus Lamond lab (University of Dundee, UK). The nucleolar proteins were separated
by SDS-PAGE and Western Blotted for CKAP4 (α-V5 in the case of CKAP4C100S/SΔE) and ﬁbrillarin. The bands were detected on ﬁlm by
ECL and quantiﬁed using ImageJ. The CKAP4 signal in each lane of the Western Blot was normalized to the ﬁbrillarin band in the same
lane. The normalized value for CKAP4 from control cells was set to 1 and the other values were set relative to control. The values in the
graph are means and SD. “∗” indicates that the means of the values were signiﬁcantly diﬀerent than serum-starved control when evaluated
using the students t-test (two-tailed. Serum starved versus APF treated P = 0.018; serum starved versus CKAP4C100S/SΔE P = 0.002;
CKAP4C100S/SΔE versus APF treated, P = 0.008; n = 3f o re a c h ) .10 International Journal of Cell Biology
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Figure 6: CKAP4C100S/SΔE expression inhibits HeLa cell prolif-
eration.H e L ac e l l sw e r em o c kt r a n s f e c t e d( F u g e n e ;c o n t r o l )o r
transfected with 100, 200, or 400ng of CKAP4C100S/SΔED N A .
After an additional 24 hours of growth, proliferation was measured
using the WST-1 proliferation assay (Biovision) according to the
manufacturer’s protocol. Each data point is the mean and SD from
12 independent wells. Statistically signiﬁcant diﬀerences in the rate
of cellular proliferation were detected for HeLa cells transfected
with 100, 200, and 400ng of CKAP4C100S/SΔE DNA versus mock-
transfected cells using the students t-test (∗P<0.001).
function as an APF mimetic and support the argument that
endogenous CKAP4 is depalmitoylated and phosphorylated
following APF binding.
3.5. Phosphorylated CKAP4 Binds to gDNA. Because CKAP4
localizes to the nucleus/nucleolus in response to APF treat-
ment and because its predicted structure includes a region
homologous to bZIP transcription factors (Figure 1), we
assessed whether CKAP4 could bind to DNA using genomic
DNA (gDNA) aﬃnity chromatography (GDAC)[22]. For
this technique, nuclear lysates from APF- or mock-treated
HeLa cells were incubated with gDNA-bound cellulose beads
in the presence of nonspeciﬁc competitor (dI-dC), and
proteins that bound DNA were isolated and separated by
SDS-PAGE followed by Western Blot with an anti-CKAP4
antibody. As shown in Figure 7(a), CKAP4 binds gDNA
in an APF-dependent manner (Lane 3) when compared to
mock-treated control (Lane 4). The CKAP4-gDNA binding
is phosphorylation dependent as CKAP4 isolated from cells
that were treated without phosphatase inhibitors prior to
APF treatment failed to bind gDNA (Lane 6). Furthermore,
in nuclear lysates from cells transfected with the V5-tagged,
phosphomimicking CKAP4 mutant (CKAP4 C100S/SΔE),
we observed enhanced binding to gDNA (Figure 7(b)). In
Figure 7(c), we show that puriﬁed rCKAP4 (C-terminal
residues 126–501, which includes the bZIP-like DNA-
binding domain) also binds gDNA. Collectively, these data
suggest that APF induces phosphorylation of CKAP4 and
that phosphorylation is required for CKAP4 to bind gDNA.
4. Discussion
CKAP4 has an established role in maintaining the struc-
ture of the ER relative to the cytoskeleton by binding to
microtubules—a function which is dependent on three N-
terminal serine residues (S3, S17, and S19) that when phos-
phorylated, cause CKAP4 to disengage from microtubules
(see Figure 1)[ 3, 7]. Expression of mutant versions of
CKAP4 that do not bind microtubules profoundly changes
ERmorphology[2].Morerecently,ourknowledgeofCKAP4
function has expanded to include it being a cell surface
receptor for APF [10], surfactant protein A (SPA) [23], and
tissue plasminogen activator (tPA) [24]. In a previous study,
we showed that palmitoylation of CKAP4 by DHHC2 is
required for its localization on the PM and for mediating
APF-induced signaling events, including inhibition of cellu-
lar proliferation and changes in gene/protein expression [6].
However, prior to the data presented here, there was nothing
known about the mechanism for APF signal transduction by
CKAP4.
Previously, we observed by immunocytochemistry that
exposing cells to APF resulted in an increased abundance
of CKAP4 in the nucleus [6]. These data suggested that
APF binding to CKAP4 on the cell surface induced its
translocation into the nucleus. In this study, we used cell-
surface labeling with Sulfo-NHS-biotin (which reacts only
with extracellular primary amines but does not bind to
proteins inside of the cell during the labeling process) to
monitor CKAP4 localization in response to APF binding.
Our results showed that biotinylated CKAP4 from the cell
surface is abundant in the nuclear fraction of HeLa cells
treated with APF, but not in untreated cells. Detection of
a relatively small amount of nonbiotinylated CKAP4 in the
nucleus of untreated cells in this experiment is consistent
with data from other experiments, indicating that CKAP4
mayhavesomeinherentnuclearfunctionnotrelatedtoAPF-
induced signal transduction, moreover, it suggests that in
ordertoblockproliferation,CKAP4inthenucleusmusthave
bound to APF at some point.
Using a series of mutants that mimic combined states
of palmitoylation and phosphorylation, we determined that
APF promotes serine phosphorylation of CKAP4; more-
over, that phosphorylation of serines 3, 17, and 19 is
required for APF-induced nuclear translocation of CKAP4,
as mutation of these residues to alanine (SΔA) inhibited this
process. Additionally, mutation of these serine residues to
glutamic acid to create a phosphomimicking form of CKAP4
(CKAP4SΔE) promoted the nuclear translocation of CKAP4International Journal of Cell Biology 11
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Figure 7: CKAP4 binds directly to genomic DNA. (a) CKAP4 binds gDNA in an APF-dependent manner (lane 3) when compared to
mock-treated control (lane 4). The CKAP4-gDNA binding is phosphorylation dependent as CKAP4 isolated from cells treated without
phosphatase inhibitors prior to APF treatment failed to bind gDNA (lane 6). As controls, we loaded APF treated nuclear lysates in lane 1 and
phosphatase/APF treated lysates in lane 5. Lane 2 is a no gDNA cellulose control. (b) The ability of transiently transfected V5-tagged, CKAP4
C100S/SΔE to bind gDNA in the absence of APF treatment (c) and the ability of puriﬁed rCKAP4 (residues 126–501, which includes the
bZIP-like DNA-binding domain) to bind gDNA were also assessed by comparing the amount of CKAP4 captured relative to what remained
in the cell lysate after binding (Sup).
in response to APF. Interestingly, a phosphomimicking
form of CKAP4 that was also constitutively depalmitoylated
localized in the nucleus without APF stimulation. These
data suggest that when CKAP4 is bound by APF on the
PM, it becomes depalmitoylated and phosphorylated and
translocates into the nucleus. In direct support of the idea
that CKAP4 must be phosphorylated to enter the nucleus,
we show by metabolic labeling with γ32P-ATP that nuclear
CKAP4 is phosphorylated. Despite using multiple methods,
we did not observe palmitoylated CKAP4 in the nucleus.
The mechanism by which CKAP4 or any other palmi-
toyl-protein becomes depalmitoylated is a matter of great
interest. However, there is very little known about how
depalmitoylation is regulated. Serines 3 and 19 reside within
a consensus site for PKC and serine 17 within a CKII site
[7]; however, whether these kinases are responsible for phos-
phorylation of these serines remains to be determined.
CKAP4 has a ∼106-amino acid cytosolic tail, a single
TM domain, and a large, extracellular/ER-luminal domain
consisting of 474 amino acids (see Figure 1). Much of the
extracellular domain, including the portion required for
oligomerization, is predicted to fold into a coiled-coil
confor-mation, with an amphipathic alpha helix rich in
basic residues comprising the C-terminal (∼80) residues
[3]. These structures are among the most common and
well-characterized domains involved in protein-protein
interactions. Moreover, amino acid residues 468–602 are
homologous to the DNA-binding domain of bZIP transcrip-
tion factors. Many details about the predicted structure of
CKAP4, its nonrandom distribution in the nucleus, and
enhanced association with nucleoli (see Figure 5), suggest
that it might bind to DNA. Genomic DNA aﬃnity chro-
matography is a straight-forward method to determine if a
protein binds to DNA without ap r i o r iknowledge of the
exact binding sites [25]. Using GDAC, we demonstrated
that CKAP4 isolated from APF-treated HeLa cells bound
genomic DNA (gDNA). Furthermore, our results show
that inclusion of phosphatase inhibitors was required for
endogenous CKAP4 to bind to gDNA, but not for binding
of the puriﬁed CKAP4 C-terminal fragment to gDNA. This
indicates that the C-terminal fragment alone, separated from
the phosphoserines near the N-terminus, is free to reside in a
conformational state that favors gDNA binding—the same
conformation that exists in the endogenous protein when
phosphorylated. Future experiments will be carried out to
identify the speciﬁc DNA sequences to which CKAP4 binds.
CKAP4 is 63kDa, homo-oligomeric, and is embedded in
membranes; these are not typical, physical properties of pro-
teins that enter the nucleus by diﬀusion. Generally, proteins
that diﬀuse into the nucleus are cytosolic and have a molec-
ular weight less than 40kDa. Proteins too large to diﬀuse
through the nuclear pore translocate with the assistance of a12 International Journal of Cell Biology
shuttle protein (or karyopherin) that is physically bound to a
nuclear localization signal (NLS) sequence of the imported
protein. CKAP4 contains a glycine-rich domain that may
act as an NLS. Similar domains found in several families of
proteins are known to mediate nuclear import [22, 26]. On-
going work indicates that this domain of CKAP4 is suﬃcient
todrivenuclearlocalizationofanonrelatedprotein(datanot
shown).
Because of its size and TM domain, it would seem
unlikely that CKAP4 would have a nuclear function. How-
ever, there is precedent for large, TM-domain proteins
entering the nucleus. The EGF (epidermal growth factor)
receptor family are glycosylated, single-pass TM domain
proteins of ∼140kDa that also translocate, unproteolyzed,
from the plasma membrane into the nucleus after ligand
binding [27]. Within the nucleus, they regulate transcrip-
tion and participate, enzymatically, in signal transduction
pathways. The idea that these proteins translocated to and
had functional activity in the nucleus, beyond their tyrosine
kinase activity at the plasma membrane, was controversial;
however, more recently, the mechanistic details about how
they make their way into the nucleus and how they function
within the nucleus are becoming clearer (reviewed in [27]).
In summary, the data presented here provide new insight
into the mechanism by which CKAP4 mediates APF signal
transduction. At the same time, we have added to a small
but growing body of literature demonstrating that a receptor
in the plasma membrane can translocate into the nucleus
after binding ligand. Finally, our data demonstrate that
CKAP4C100S/SΔE has APF-like activity as it localizes to the
nucleus and inhibits proliferation without binding to APF.
This ﬁnding suggests that CKAP4C100S/SΔEc o u l db eu s e d
to treat hyperproliferative diseases such as cancer. APF itself
has been proposed as an anticancer therapy [28].
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